ATLANTA — If you want to avoid shingles — a condition that comes with a painful rash — there is a vaccine available. But studies have shown that protection generated by the vaccine declines quickly.
A new vaccine, however, is being considered for approval, and if and when the Food and Drug Administration gives it the green light, its may hit the market with a highly desirably preferential rating from an influential panel of vaccine experts.
Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
““A preferential recommendation will make a difference here,” Bresnitz told the committee. “Let the market determine what happens here.”
Translation: Let marketing, not the data, decide.